Immune-Enhancing Effect of Submerged Culture of Ceriporia lacerata Mycelia on Cyclophosphamide-Induced Immunosuppressed Mice and the Underlying Mechanisms in Macrophages.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
    • Abstract:
      The white-rot fungi Ceriporia lacerata is used in bioremediation, such as lignocellulose degradation, in nature. Submerged cultures and extracts of C. lacerata mycelia (CLM) have been reported to contain various active ingredients, including β-glucan and extracellular polysaccharides, and to exert anti-diabetogenic properties in mice and cell lines. However, the immunostimulatory effects have not yet been reported. This study aimed to identify the immunomodulatory effects, and underlying mechanisms thereof, of submerged cultures of CLM using RAW264.7 macrophages and cyclophosphamide (CTX)-induced immunosuppression in mice. Compared to CTX-induced immunosuppressed mice, the spleen and thymus indexes in mice orally administered CLM were significantly increased; body weight loss was alleviated; and natural killer (NK) cytotoxicity, lymphocyte proliferation, and cytokine (tumor necrosis factor [TNF]-α, interferon [IFN]-γ, and interleukin [IL]-2) production were elevated in the serum. In RAW264.7 macrophages, treatment with CLM induced phagocytic activity, increased the production of nitric oxide (NO), and promoted mRNA expression of the immunomodulatory cytokines TNF-α, IFN-γ, IL-1β, IL-6, IL-10, and IL-12. In addition, CLM increased the inducible NO synthase (iNOS) concentration in macrophages, similar to lipopolysaccharide (LPS) stimulation. Mechanistic studies showed that CLM induced the activation of the NF-κB, PI3k/Akt, ERK1/2, and JNK1/2 pathways. Moreover, the phosphorylation of NF-κB and IκB induced by CLM in RAW264.7 cells was suppressed by specific MAPKs and PI3K inhibitors. Further experiments with a TLR4 inhibitor demonstrated that the production of TNF-α, IL-1β, and IL-6 induced by CLM was decreased after TLR4 was blocked. Overall, CLM protected against CTX-induced adverse reactions by enhancing humoral and cellular immune functions, and has potential as an immunomodulatory agent.
    • References:
      Hum Vaccin Immunother. 2015;11(11):2659-63. (PMID: 26317776)
      Nutr J. 2014 Apr 28;13:38. (PMID: 24774968)
      Nutr Res. 2020 Mar;75:15-31. (PMID: 31955012)
      Food Nutr Res. 2017 Jul 9;61(1):1344523. (PMID: 28747866)
      Immune Netw. 2011 Aug;11(4):191-5. (PMID: 22039366)
      Front Immunol. 2018 Apr 16;9:673. (PMID: 29755450)
      Adv Immunol. 1995;58:1-27. (PMID: 7741027)
      Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):43-54. (PMID: 11516778)
      Eur J Pharmacol. 2013 Aug 15;714(1-3):120-4. (PMID: 23791611)
      J Neurol Sci. 2014 May 15;340(1-2):117-22. (PMID: 24655735)
      Ann Allergy. 1994 Feb;72(2):125-8. (PMID: 8109801)
      Int J Mol Med. 2013 Jul;32(1):179-86. (PMID: 23624822)
      Eur J Nutr. 2005 Dec;44(8):509-16. (PMID: 15719157)
      Int Immunopharmacol. 2017 Nov;52:119-126. (PMID: 28898768)
      Int J Prev Med. 2014 Dec;5(12):1487-99. (PMID: 25709784)
      Microorganisms. 2020 Aug 02;8(8):. (PMID: 32748895)
      Microbes Infect. 2016 Dec;18(12):735-746. (PMID: 27866863)
      J Exp Med. 2000 Jul 17;192(2):227-36. (PMID: 10899909)
      Carbohydr Polym. 2016 May 20;142:259-67. (PMID: 26917398)
      PLoS One. 2018 Oct 8;13(10):e0204152. (PMID: 30296293)
      Adv Exp Med Biol. 2017;1003:3-14. (PMID: 28667551)
      Integr Med (Encinitas). 2014 Feb;13(1):32-44. (PMID: 26770080)
      J Microbiol. 2007 Dec;45(6):485-91. (PMID: 18176529)
      BMC Complement Med Ther. 2021 Oct 26;21(1):269. (PMID: 34702240)
      Biol Res. 2014 Apr 28;47:15. (PMID: 25027489)
      J Thorac Dis. 2018 Feb;10(Suppl 3):S480-S489. (PMID: 29593893)
      Med Mycol. 2018 Aug 1;56(6):711-722. (PMID: 29087533)
      Front Immunol. 2014 Nov 28;5:614. (PMID: 25506346)
    • Grant Information:
      none 2021 Collaborative R&BD Program of The Food Industry Promotional Agency of Korea.
    • Contributed Indexing:
      Keywords: Ceriporia lacerate; cyclophosphamide; cytokines; immunomodulatory; lymphocytes; macrophages
    • Accession Number:
      0 (Cytokines)
      0 (Immunomodulating Agents)
      0 (NF-kappa B)
      31C4KY9ESH (Nitric Oxide)
      8N3DW7272P (Cyclophosphamide)
    • Subject Terms:
      Emmia lacerata
    • Publication Date:
      Date Created: 20220121 Date Completed: 20220304 Latest Revision: 20220304
    • Publication Date:
      20221213
    • Accession Number:
      PMC8775494
    • Accession Number:
      10.3390/ijms23020597
    • Accession Number:
      35054804